| human | Q5 |
| P496 | ORCID iD | 0000-0002-2163-6644 |
| P7293 | PLWABN ID | 9810819856405606 |
| P214 | VIAF ID | 328149066622665602229 |
| P69 | educated at | Karolinska Institutet | Q219564 |
| P108 | employer | Karolinska Institutet | Q219564 |
| Karolinska University Hospital | Q1734280 | ||
| P734 | family name | Mattsson | Q1550403 |
| Mattsson | Q1550403 | ||
| Mattsson | Q1550403 | ||
| P735 | given name | Jonas | Q16646115 |
| Jonas | Q16646115 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q28553703 | 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one |
| Q52779950 | A Preliminary Report: Radical Surgery and Stem Cell Transplantation for the Treatment of Patients With Pancreatic Cancer. |
| Q43573854 | A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation |
| Q62588671 | A graft-versus-colonic cancer effect of allogeneic stem cell transplantation |
| Q50967594 | A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors. |
| Q73279459 | A low incidence of grade II to IV acute GVHD, but high mortality from infection using HLA-A, -B, and -DR-identical unrelated donors and immunosuppression with ATG, cyclosporine, and methotrexate |
| Q35012553 | A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation |
| Q46822195 | A prospective randomized study using N-acetyl-L-cysteine for early liver toxicity after allogeneic hematopoietic stem cell transplantation |
| Q44282612 | A prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation |
| Q33573529 | A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation |
| Q40631727 | A prospective randomized trial of Filgrastim (r-metHuG-CSF) given at different times after unrelated bone marrow transplantation |
| Q92901376 | A systematic literature review of incidence, mortality, and relapse of patients diagnosed with chronic graft versus host disease |
| Q51022488 | Allogeneic Hematopoietic Cell Transplantation for GATA2 Deficiency in a Patient With Disseminated Human Papillomavirus Disease. |
| Q83781694 | Allogeneic hematopoietic SCT in patients with non-malignant diseases, and importance of chimerism |
| Q82811353 | Allogeneic hematopoietic stem cell transplantation for inherited disorders: experience in a single center |
| Q50777164 | Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival. |
| Q45166919 | Allogenic stem cell transplantation for nonmalignant disorders using matched unrelated donors |
| Q34413233 | Alpha/beta T-cell depleted grafts as an immunological booster to treat graft failure after hematopoietic stem cell transplantation with HLA-matched related and unrelated donors |
| Q43733296 | Altered expression of receptors for thyroid hormone and insulin-like growth factor-I during reconstitution after allogeneic hematopoietic stem cell transplantation |
| Q62588674 | An allogeneic anti-cancer effect after hematopoietic stem cell transplantation |
| Q73418809 | An ethnic role for chronic, but not acute, graft-versus-host disease after HLA-identical sibling stem cell transplantation |
| Q73669456 | An ethnic role for chronic, but not acute, graft-versus-host disease after HLA-identical sibling stem cell transplantation |
| Q53081594 | Analysis of donor and recipient ABO incompatibility and antibody-associated complications after allogeneic stem cell transplantation with reduced-intensity conditioning. |
| Q48222173 | Assessment of TREC, KREC and telomere length in long-term survivors after allogeneic HSCT: the role of GvHD and graft source and evidence for telomere homeostasis in young recipients |
| Q73170758 | Bilateral subdural haematomas following lumbar puncture in three haematopoietic stem cell transplant recipients |
| Q53536804 | Bone marrow aspiration technique has deteriorated in recent years. |
| Q44779079 | C-reactive protein levels before reduced-intensity conditioning predict outcome after allogeneic stem cell transplantation |
| Q47190740 | CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile |
| Q81072219 | Case-control comparison of at-home and hospital care for allogeneic hematopoietic stem-cell transplantation: the role of oral nutrition |
| Q41694140 | Characterization of infiltrating lymphocytes in human benign and malignant prostate tissue |
| Q51040027 | Characterization of long-term mixed donor-donor chimerism after double cord blood transplantation. |
| Q40730089 | Chimerism and use of mesenchymal stem cells in umbilical cord blood transplantation |
| Q45264209 | Chimerism patterns of long-term stable mixed chimeras posthematopoietic stem cell transplantation in patients with nonmalignant diseases: follow-up of long-term stable mixed chimerism patients. |
| Q39923828 | Clinical expansion of cord blood-derived T cells for use as donor lymphocyte infusion after cord blood transplantation |
| Q44649880 | Clinical tolerance after allogeneic hematopoietic stem cell transplantation: a study of influencing factors |
| Q33809599 | Combining Flow and Mass Cytometry in the Search for Biomarkers in Chronic Graft-versus-Host Disease |
| Q51146472 | Comparison of algorithms for oral busulphan area under the concentration-time curve limited sampling estimate. |
| Q99406587 | Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination |
| Q39357594 | Cord blood T cells cultured with IL-7 in addition to IL-2 exhibit a higher degree of polyfunctionality and superior proliferation potential |
| Q42241622 | Cord blood graft composition impacts the clinical outcome of allogeneic stem cell transplantation |
| Q37505854 | Cyclophosphamide alters the gene expression profile in patients treated with high doses prior to stem cell transplantation. |
| Q84136247 | Cytotoxic crossmatch analysis before allo-SCT is a poor diagnostic tool for prediction of rejection |
| Q81778108 | Decreased serum levels of clara cell secretory protein (CC16) are associated with bronchiolitis obliterans and may permit early diagnosis in patients after allogeneic stem-cell transplantation |
| Q53584539 | Decreasing mortality rate in early pneumonia following hematopoietic stem cell transplantation. |
| Q83067678 | Donor lymphocyte infusion may reduce the incidence of bronchiolitis obliterans after allogeneic stem cell transplantation |
| Q44981292 | Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. |
| Q84707051 | Early detection of relapse in patients with myelodysplastic syndrome after allo-SCT |
| Q84401319 | Effects of different serum-levels of ATG after unrelated donor umbilical cord blood transplantation |
| Q74615208 | Engraftment and chimerism, particularly of T- and B-cells, in children undergoing allogeneic bone marrow transplantation |
| Q83781690 | Ethmoiditis-associated apex syndrome may result in temporary blindness after allo-SCT |
| Q53019007 | Expanded umbilical cord blood T cells used as donor lymphocyte infusions after umbilical cord blood transplantation. |
| Q45771063 | Expansion of T-cells from the cord blood graft as a predictive tool for complications and outcome of cord blood transplantation. |
| Q93099609 | Facing the future: challenges and opportunities in adoptive T cell therapy in cancer |
| Q73869542 | Factors affecting risk of relapse and leukemia-free survival in HLA-identical sibling marrow transplant recipients with leukemia |
| Q85215805 | Factors with an impact on chimerism development and long-term survival after umbilical cord blood transplantation |
| Q85888828 | Fetal membrane cells for treatment of steroid-refractory acute graft-versus-host disease |
| Q40457429 | Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem cell transplantation for treatment of non-malignant diseases. |
| Q44564294 | Fractionated TBI correlates with less T cell mixed chimerism but increased risk of relapse compared to busulphan in patients with haematological malignancies after allogeneic stem cell transplantation |
| Q82208464 | GVHD prophylaxis using low-dose cyclosporine improves survival in leukaemic recipients of HLA-identical sibling transplants |
| Q43988469 | General health, symptom occurrence, and self-efficacy in adult survivors after allogeneic hematopoietic stem cell transplantation: a cross-sectional comparison between hospital care and home care |
| Q80730905 | Genomic tissue typing and optimal antithymocyte globuline dose using unrelated donors results in similar survival and relapse as HLA-identical siblings in haematopoietic stem-cell transplantation for leukaemia |
| Q37045988 | Graft failure after allogeneic hematopoietic cell transplantation |
| Q33404733 | Graft failure in the modern era of allogeneic hematopoietic SCT. |
| Q48013821 | Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia |
| Q84977190 | Granulocyte colony-stimulating factor induced acute and chronic graft-versus-host disease |
| Q58861766 | Hematopoietic stem cell transplantation in severe congenital neutropenia |
| Q81227386 | Hemorrhagic cystitis: a retrospective single-center survey |
| Q52839305 | High incidence of severe chronic GvHD after HSCT with sibling donors. A single center analysis. |
| Q64112799 | Higher response rates in patients with severe chronic skin graft-versus-host disease treated with extracorporeal photopheresis |
| Q43486658 | Home care during neutropenia after allogeneic hematopoietic stem cell transplantation in children and adolescents is safe and may be more advantageous than isolation in hospital |
| Q39479448 | Hospital care or home care after allogeneic hematopoietic stem cell transplantation--patients' experiences of care and support. |
| Q92703095 | Humanistic burden of patients with chronic graft-versus-host disease - systematic literature review of health-related quality of life and functional status |
| Q53660446 | Identification of maternal hematopoietic cells in a 2nd-trimester fetus. |
| Q50789212 | Immune modulation to prevent antibody-mediated rejection after allogeneic hematopoietic stem cell transplantation. |
| Q31153469 | Impact of Pretransplantation Indices in Hematopoietic Stem Cell Transplantation: Knowledge of Center-Specific Outcome Data Is Pivotal before Making Index-Based Decisions |
| Q58789014 | Improved Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Recent Years. A Single-Center Study |
| Q73316118 | Improved survival after bone marrow transplantation for early leukemia using busulfan-cyclophosphamide and individualized prophylaxis against graft-versus-host disease: a long-term follow-up |
| Q44205908 | Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study |
| Q83414944 | In vitro or in vivo expansion before adoptive T-cell therapy? |
| Q42234975 | Incidence, risk factors, and outcome of bloodstream infections during the pre-engraftment phase in 521 allogeneic hematopoietic stem cell transplantations |
| Q51648860 | Increased frequency and responsiveness of PSA-specific T cells after allogeneic hematopoetic stem-cell transplantation. |
| Q54672157 | Increased gene expression of chemokine receptors is correlated with acute graft-versus-host disease after allogeneic stem cell transplantation. |
| Q44741792 | Increased immune transcript levels are correlated with acute graft-versus-host disease and cytomegalovirus response after allogeneic stem cell transplantation |
| Q44351289 | Increased levels of immune transcript in patients with acute GVHD after allogeneic stem cell transplantation |
| Q58788918 | Increased risk of gastrointestinal acute GVHD following the addition of melphalan to busulfan/cyclophosphamide conditioning |
| Q64249488 | Individualization of Hematopoietic Stem Cell Transplantation Using Alpha/Beta T-Cell Depletion |
| Q78410295 | Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation |
| Q84392996 | Leukemia lineage-specific chimerism analysis and molecular monitoring improve outcome of donor lymphocyte infusions |
| Q77378864 | Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation |
| Q44405404 | Liver transplantation followed by adjuvant nonmyeloablative hemopoietic stem cell transplantation for advanced primary liver cancer in humans |
| Q40994796 | Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid Cancer |
| Q36010605 | Long-Term Stable Mixed Chimerism after Hematopoietic Stem Cell Transplantation in Patients with Non-Malignant Disease, Shall We Be Tolerant? |
| Q73293905 | Long-term persistence of oligoclonal serum IgM repertoires in patients treated with allogeneic bone marrow transplantation (BMT) |
| Q44856492 | Low incidence of acute graft-versus-host disease, using unrelated HLA-A-, HLA-B-, and HLA-DR-compatible donors and conditioning, including anti-T-cell antibodies |
| Q44351254 | Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma |
| Q58789257 | Lung Epithelial Cells and Type II Pneumocytes of Donor Origin After Allogeneic Hematopoietic Stem Cell Transplantation |
| Q80390081 | Major ABO blood group mismatch increases the risk for graft failure after unrelated donor hematopoietic stem cell transplantation |
| Q33403751 | Major surgery in a neutropenic patient undergoing allogeneic stem cell transplantation for high risk myelofibrosis |
| Q45085421 | Many days at home during neutropenia after allogeneic hematopoietic stem cell transplantation correlates with low incidence of acute graft-versus-host disease |
| Q52005635 | Memory B lymphocytes determine repertoire oligoclonality early after haematopoietic stem cell transplantation. |
| Q84810984 | Mesenchymal stem cells inhibit thymic reconstitution after allogeneic cord blood transplantation |
| Q44505579 | Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia |
| Q73446161 | Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease |
| Q43885610 | Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation |
| Q73784852 | Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia |
| Q53677301 | Molecular monitoring of T-cell chimerism early after allogeneic stem cell transplantation may predict the occurrence of acute GVHD grades II-IV. |
| Q54195260 | Myeloablative conditioning for hematopoietic stem-cell transplantation in patients with non-malignant diseases. |
| Q73756692 | N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation |
| Q38782925 | No effect of HLA-C mismatch after allogeneic hematopoietic stem cell transplantation with unrelated donors and T-cell depletion in patients with hematological malignancies |
| Q80813551 | No impact of NOD2/CARD15 on outcome after SCT |
| Q49848728 | Norovirus CausingSevere Gastrointestinal Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: a Retrospective Analysis |
| Q81964910 | Novel antibodies to the donor stem cell population CD34+/VEGFR-2+ are associated with rejection after hematopoietic stem cell transplantation |
| Q87543789 | Novel method to characterize immune cells from human prostate tissue |
| Q82561584 | Outcome of haematopoietic stem cell transplantation in patients transplanted with matched unrelated donors vs allele-mismatched donors: a single centre study |
| Q99632138 | Patient-reported symptom burden of chronic graft versus host disease: a systematic literature review |
| Q40599078 | Polyclonal anti-T-cell globulin as part of the preparative regimen for pediatric allogeneic stem-cell transplantation |
| Q73417440 | Poor immune reconstitution after four or five major HLA antigens mismatched T cell-depleted allogeneic and autologous stem cell transplantation |
| Q80238263 | Poor oral nutrition after allogeneic stem cell transplantation correlates significantly with severe graft-versus-host disease |
| Q41886285 | Posaconazole concentrations in human tissues after allogeneic stem cell transplantation |
| Q43789729 | Pre-engraftment blood stream infection is a risk factor for acute GVHD grades II-IV. |
| Q62118107 | Pre-formulation investigations for establishing a protocol for treosulfan handling and activation |
| Q45888757 | Prenatal T-cell reconstitution after in utero transplantation with fetal liver cells in a patient with X-linked severe combined immunodeficiency |
| Q37269077 | Progression of benign prostatic hyperplasia is associated with pro-inflammatory mediators and chronic activation of prostate-infiltrating lymphocytes |
| Q41046376 | Prolonged outbreak of adenovirus A31 in allogeneic stem cell transplant recipients |
| Q41742166 | Quality of the hematopoietic stem cell graft affects the clinical outcome of allogeneic stem cell transplantation |
| Q43146785 | Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT. |
| Q45356159 | Rapid salvage treatment with virus-specific T cells for therapy-resistant disease |
| Q37236062 | Recent progress in allogeneic stem cell transplantation. |
| Q81255322 | Reconstitution of the Ig heavy chain CDR3 repertoire after allogeneic haematopoietic stem cell transplantation with myeloablative or reduced-intensity conditioning regimens |
| Q42261265 | Reduced IL-7 responsiveness defined by signal transducer and activator of transcription 5 phosphorylation in T cells may be a marker for increased risk of developing cytomegalovirus disease in patients after hematopoietic stem cell transplantation |
| Q45014439 | Respiratory syncytial virus infection in recipients of allogeneic stem-cell transplantation: a retrospective study of the incidence, clinical features, and outcome |
| Q77658507 | Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients |
| Q42102663 | Risk Factors for Invasive Mold Infections and Implications for Choice of Prophylaxis after Allogeneic Stem Cell Transplantation |
| Q37552052 | Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation |
| Q51729292 | Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study. |
| Q50856033 | Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. |
| Q78778794 | Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation |
| Q74517229 | Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination |
| Q58086780 | Risks and Benefits of Sex-Mismatched Hematopoietic Cell Transplantation Differ By Conditioning Strategy |
| Q36779768 | Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy |
| Q85194339 | Second allogeneic hematopoietic stem cell transplantation: a treatment for graft failure |
| Q34325244 | Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning |
| Q84491334 | Sequential Organ Failure Assessment predicts the outcome of SCT recipients admitted to intensive care unit |
| Q73412981 | Serum levels of cytokines correlate to donor chimerism and acute graft-vs.-host disease after haematopoietic stem cell transplantation |
| Q84968522 | Sirolimus and tacrolimus as immune prophylaxis compared to cyclosporine with or without methotrexate in patients undergoing allogeneic haematopoietic stem cell transplantation for non-malignant disorders |
| Q54443654 | Splenectomy prior to allogeneic hematopoietic SCT increases the risk of post-transplant lymphoproliferative disease. |
| Q84443325 | Stable mixed donor-donor chimerism after double cord blood transplantation |
| Q85157583 | Standardization of Aspergillus PCR is needed |
| Q38096025 | Systems level immune response analysis and personalized medicine |
| Q73575606 | T cell mixed chimerism is significantly correlated to a decreased risk of acute graft-versus-host disease after allogeneic stem cell transplantation |
| Q81568350 | T-cell receptor Vbeta repertoire after myeloablative and reduced intensity conditioning allogeneic haematopoietic stem cell transplantation |
| Q87422427 | T-cell receptor excision circle levels after allogeneic stem cell transplantation are predictive of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome |
| Q45383857 | Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction |
| Q78630210 | The TNFd4 allele is correlated to moderate-to-severe acute graft-versus-host disease after allogeneic stem cell transplantation |
| Q51808142 | The clinical importance of bronchoalveolar lavage in allogeneic SCT patients with pneumonia. |
| Q54978683 | The effect of N-acetyl-l-cysteine (NAC) on liver toxicity and clinical outcome after hematopoietic stem cell transplantation. |
| Q78536984 | The graft-versus-leukaemia effect in haematopoietic stem cell transplantation using unrelated donors |
| Q53676885 | The pathophysiology of acute graft-versus-host disease. |
| Q74459338 | The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia |
| Q83193884 | Thymic function after allogeneic stem cell transplantation is dependent on graft source and predictive of long term survival |
| Q48165128 | Toxicological effects of fludarabine and treosulfan conditioning before allogeneic stem-cell transplantation |
| Q73893056 | Transplantation of autologous and allogeneic bone marrow with liver from a cadaveric donor for primary liver cancer |
| Q74256241 | Transplantation with unrelated bone marrow in leukaemic patients above 40 years of age |
| Q73869535 | Transplantation with unrelated bone marrow in leukemic patients above 40 years of age |
| Q47416112 | Treatment with mesenchymal stromal cells is a risk factor for pneumonia-related death after allogeneic hematopoietic stem cell transplantation |
| Q81909391 | Unrelated cord blood and mismatched unrelated volunteer donor transplants, two alternatives in patients who lack an HLA-identical donor |
| Q78151940 | Unrelated donor stem cell transplantation after autologous transplantation: experience of a single center |
| Q79234894 | Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning |
| Q37990389 | Update on viral infections in lung transplantation |
| Q46434551 | Using reduced intensity conditioning and HLA-identical sibling donors, antithymocyte globulin increases the risk of relapse, which can be overcome by a high stem cell dose |
| Q42211197 | Varicella-zoster reactivation after allogeneic stem cell transplantation without routine prophylaxis--the incidence remains high |
Search more.